After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

The FDA’s vaccine advisory committee has unanimously recommended updating the strains included in this fall’s flu vaccines, endorsing a new variant that emerged late in 2025 and quickly became ...

The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...

The European Medicines Agency has recommended approval of a mCombriax, an mRNA vaccine that protects against COVID-19 and influenza, for people aged 50 years or older, which would allow the continent ...

Shares of Moderna MRNA rose about 4% on Friday after the company announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to ...

Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA’s decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial. The FDA imposed clinical holds on the ...

The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver ...

European regulators gave the green light to Moderna Inc.’s novel combination flu and Covid shot, handing a victory to the embattled vaccine maker as it struggles to get the same shot approved in the ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe. The Committee for Medicinal Products for ...

Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...

A single spritz could eventually offer simultaneous protection against several infectious diseases. Researchers at Stanford Medicine have developed a new vaccine that could prevent multiple viruses at ...